H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Weakness in this biotech stock is a buying opportunity: Mizuho
July 31, 2026 9:00 AM EDTMizuho reiterated an Outperform rating and $65 price target on a key biotech stock in a note on Friday, telling investors that a selloff following the drugmaker's second-quarter results is a buying opportunity.
Analyst Uy Ear said Alkermes (NASDAQ: ALKS) posted a solid quarter, with product sales, manufacturing and royalty revenues broadly in line with estimates... More
